Bionor Pharma: Alive And Kicking
Edison | May 15, 2014 02:40AM ET
Encouraging data in the last few months are supportive of Bionor Pharma ASA's (OSLO:BIONOR) Vacc-4x strategy, with patient response variability highlighting the importance of developing predictive biomarkers. Although reboosting with Vacc-4x did not show a further reduction in viral load, the reboost data provide more evidence of Vacc-4x’s ability to induce an immune response to HIV. This could be enhanced by boosting the immune system and by releasing hidden HIV reservoirs; both are under investigation.
Bionor’s strategy to develop Vacc-4x as a potential functional cure for HIV remains intact. This strategy encompasses three key elements: Kick, Kill and Boost. Vacc-4x has already demonstrated viral load reduction (‘Kill’) with supportive data from the recent reboost study. ‘Boost & Kill’ and ‘Kick & Kill’ trials are ongoing, with data expected in Q414 and H215, respectively. Bionor has disclosed that some patients in the recent reboost trial did show a stronger response to Vacc-4x. While baseline characteristics of these patients are not yet known, differing response levels according to anti-C5 levels were recently reported in a subset analysis. Analysing and understanding why certain patients respond better to Vacc-4x and the development of predictive biomarkers could be key for maximising value.
h3 Data support strategy/h3In the last few months encouraging data from Bionor’s two HIV vaccines have been released, in addition to first data confirming the ability to for an HDACi to ‘kick’ awake HIV reservoirs. In the latter, data from the first part of the HDACi combo study have demonstrated that romidepsin (‘Kick’) can successfully reactivate latent HIV reservoirs. Data from the Phase I Vacc-C5 trial confirmed it is safe and well tolerated and that it can increase anti-C5 antibody levels in patients with low baseline anti-C5. Finally, although Vacc-4x reboost data did not show any additional significant lowering of the 2010 viral load set point, this small trial did provide additional evidence of Vacc-4x’s ability to lower viral load (‘Kill’).
h3 Valuation: Risk-adjusted NPV of NOK888m/h3Our underlying Vacc-4x assumptions are unchanged, with our rNPV now NOK888m (from NOK882m) owing to updated net cash and rolling our valuation forwards. Net cash of NOK89m at end March should be sufficient to fund operations into H215, which could allow for the complete HDACi combination data.
Get The News You Want
To Read the Entire Report Please Click on the pdf File Below
/h3
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.